BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect 2018;24:308.e5-8. [PMID: 28811242 DOI: 10.1016/j.cmi.2017.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
2 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
3 Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020;99:e21270. [PMID: 32791706 DOI: 10.1097/MD.0000000000021270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C, Coppola N. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018;46:761-83. [DOI: 10.1007/s15010-018-1188-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
5 Simicic P, Grgic I, Santak M, Vince A, Lepej SZ. Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia. Microb Pathog 2019;136:103694. [PMID: 31446041 DOI: 10.1016/j.micpath.2019.103694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Li HC, Yang CH, Lo SY. Hepatitis C Viral Replication Complex. Viruses 2021;13:520. [PMID: 33809897 DOI: 10.3390/v13030520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Papaluca T, O'Keefe J, Bowden S, Doyle JS, Stoove M, Hellard M, Thompson AJ. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol 2019;120:84-7. [PMID: 31606586 DOI: 10.1016/j.jcv.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]